User menu

Catalase down-regulation in cancer cells exposed to arsenic trioxide is involved in their increased sensitivity to a pro-oxidant treatment.

Bibliographic reference Glorieux, Christophe ; Buc Calderon, Pedro. Catalase down-regulation in cancer cells exposed to arsenic trioxide is involved in their increased sensitivity to a pro-oxidant treatment.. In: Cancer Cell International, Vol. 18, p. 24 [1-9] (2018)
Permanent URL
  1. Watanabe Takayuki, Hirano Seishiro, Metabolism of arsenic and its toxicological relevance, 10.1007/s00204-012-0904-5
  2. Chendamarai E., Balasubramanian P., George B., Viswabandya A., Abraham A., Ahmed R., Alex A. A., Ganesan S., Lakshmi K. M., Sitaram U., Nair S. C., Chandy M., Janet N. B., Srivastava V. M., Srivastava A., Mathews V., Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy, 10.1182/blood-2011-11-393264
  3. Iland H. J., Bradstock K., Supple S. G., Catalano A., Collins M., Hertzberg M., Browett P., Grigg A., Firkin F., Hugman A., Reynolds J., Di Iulio J., Tiley C., Taylor K., Filshie R., Seldon M., Taper J., Szer J., Moore J., Bashford J., Seymour J. F., , All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4), 10.1182/blood-2012-02-410746
  4. Park J. H., ATRA plus arsenic gets another "A" in APL, 10.1182/blood-2012-07-439547
  5. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354–60.
  6. Chow Stephanie K.Y., Chan Judy Y.W., Fung K.P., Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells, 10.1002/jcb.20102
  7. Ling Y.-H., Arsenic Trioxide Produces Polymerization of Microtubules and Mitotic Arrest before Apoptosis in Human Tumor Cell Lines, 10.1124/mol.62.3.529
  8. Lu J., Chew E.-H., Holmgren A., Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide, 10.1073/pnas.0701549104
  9. Emadi Ashkan, Gore Steven D., Arsenic trioxide — An old drug rediscovered, 10.1016/j.blre.2010.04.001
  10. Lang E., Grudic A., Pankiv S., Bruserud O., Simonsen A., Bjerkvig R., Bjoras M., Boe S. O., The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling, 10.1182/blood-2011-10-388496
  11. Zhang X. W., Yan X. J., Zhou Z. R., Yang F. F., Wu Z. Y., Sun H. B., Liang W. X., Song A. X., Lallemand-Breitenbach V., Jeanne M., Zhang Q. Y., Yang H. Y., Huang Q. H., Zhou G. B., Tong J. H., Zhang Y., Wu J. H., Hu H. Y., de The H., Chen S. J., Chen Z., Arsenic Trioxide Controls the Fate of the PML-RAR  Oncoprotein by Directly Binding PML, 10.1126/science.1183424
  12. Chou W.-C., Jie C., Kenedy A. A., Jones R. J., Trush M. A., Dang C. V., Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells, 10.1073/pnas.0306687101
  13. Varghese MV, Manju A, Abhilash M, Paul MV, Abhilash S, Nair RH. Oxidative stress induced by the chemotherapeutic agent arsenic trioxide. 3. Biotech. 2014;4:425–30.
  14. Glorieux Christophe, Dejeans Nicolas, Sid Brice, Beck Raphaël, Calderon Pedro Buc, Verrax Julien, Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy, 10.1016/j.bcp.2011.06.007
  15. Glorieux Christophe, Zamocky Marcel, Sandoval Juan Marcelo, Verrax Julien, Calderon Pedro Buc, Regulation of catalase expression in healthy and cancerous cells, 10.1016/j.freeradbiomed.2015.06.017
  16. Glorieux Christophe, Auquier Julien, Dejeans Nicolas, Sid Brice, Demoulin Jean-Baptiste, Bertrand Luc, Verrax Julien, Calderon Pedro Buc, Catalase expression in MCF-7 breast cancer cells is mainly controlled by PI3K/Akt/mTor signaling pathway, 10.1016/j.bcp.2014.02.025
  17. Glorieux Christophe, Sandoval Juan Marcelo, Fattaccioli Antoine, Dejeans Nicolas, Garbe James C., Dieu Marc, Verrax Julien, Renard Patricia, Huang Peng, Calderon Pedro Buc, Chromatin remodeling regulates catalase expression during cancer cells adaptation to chronic oxidative stress, 10.1016/j.freeradbiomed.2016.08.031
  18. Dejeans Nicolas, Glorieux Christophe, Guenin Samuel, Beck Raphael, Sid Brice, Rousseau Rejane, Bisig Bettina, Delvenne Philippe, Buc Calderon Pedro, Verrax Julien, Overexpression of GRP94 in breast cancer cells resistant to oxidative stress promotes high levels of cancer cell proliferation and migration: Implications for tumor recurrence, 10.1016/j.freeradbiomed.2011.12.019
  19. Glorieux Christophe, Sandoval Juan Marcelo, Dejeans Nicolas, Ameye Geneviève, Poirel Hélène Antoine, Verrax Julien, Calderon Pedro Buc, Overexpression of NAD(P)H:quinone oxidoreductase 1 (NQO1) and genomic gain of the NQO1 locus modulates breast cancer cell sensitivity to quinones, 10.1016/j.lfs.2015.12.017
  20. Verrax J., Pedrosa R., Beck R., Dejeans N., Taper H., Calderon P., In Situ Modulation of Oxidative Stress: A Novel and Efficient Strategy to Kill Cancer Cells, 10.2174/092986709788186057
  21. Verrax Julien, Vanbever Stéphanie, Stockis Julie, Taper Henryk, Calderon Pedro Buc, Role of glycolysis inhibition and poly(ADP-ribose) polymerase activation in necrotic-like cell death caused by ascorbate/menadione-induced oxidative stress in K562 human chronic myelogenous leukemic cells, 10.1002/ijc.22439
  22. Garbe J. C., Bhattacharya S., Merchant B., Bassett E., Swisshelm K., Feiler H. S., Wyrobek A. J., Stampfer M. R., Molecular Distinctions between Stasis and Telomere Attrition Senescence Barriers Shown by Long-term Culture of Normal Human Mammary Epithelial Cells, 10.1158/0008-5472.can-09-0270
  23. Bai Jingxiang, Cederbaum Arthur I., Overexpression of Catalase in the Mitochondrial or Cytosolic Compartment Increases Sensitivity of HepG2 Cells to Tumor Necrosis Factor-α-induced Apoptosis, 10.1074/jbc.m000438200
  24. Mosmann Tim, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays, 10.1016/0022-1759(83)90303-4
  25. Nenoi M, Ichimura S, Mita K, Yukawa O, Cartwright IL. Regulation of the catalase gene promoter by Sp1, CCAAT-recognizing factors, and a WT1/Egr-related factor in hydrogen peroxide-resistant HP100 cells. Cancer Res. 2001;61:5885–94.
  26. Yoo J H, Erzurum S C, Hay J G, Lemarchand P, Crystal R G, Vulnerability of the human airway epithelium to hyperoxia. Constitutive expression of the catalase gene in human bronchial epithelial cells despite oxidant stress., 10.1172/jci116959
  27. Margoliash E., Novogrodsky A., Schejter A., Irreversible reaction of 3-amino-1:2:4-triazole and related inhibitors with the protein of catalase, 10.1042/bj0740339
  28. Beck Raphaël, Pedrosa Rozangela Curi, Dejeans Nicolas, Glorieux Christophe, Levêque Philippe, Gallez Bernard, Taper Henryk, Eeckhoudt Stéphane, Knoops Laurent, Calderon Pedro Buc, Verrax Julien, Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study, 10.1007/s10637-010-9441-3
  29. Verrax Julien, Cadrobbi Julie, Marques Carole, Taper Henryk, Habraken Yvette, Piette Jacques, Calderon Pedro Buc, Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic caspase-3 independent form of cell death, 10.1023/b:appt.0000018804.26026.1a
  30. Verrax Julien, Stockis Julie, Tison Aurélie, Taper Henryk S., Calderon Pedro Buc, Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice, 10.1016/j.bcp.2006.05.025
  31. Bachleitner-Hofmann T., Gisslinger B., Grumbeck E., Gisslinger H., Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?, 10.1046/j.1365-2141.2001.02608.x
  32. Noguera Nélida I., Pelosi Elvira, Angelini Daniela F., Piredda Maria Liliana, Guerrera Gisella, Piras Eleonora, Battistini Luca, Massai Lauretta, Berardi Anna, Catalano Gianfranco, Cicconi Laura, Castelli Germana, D’Angiò Agnese, Pasquini Luca, Graziani Grazia, Fioritoni Giuseppe, Voso Maria Teresa, Mastrangelo Domenico, Testa Ugo, Lo-Coco Francesco, High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro, 10.18632/oncotarget.15925
  33. Wang Yang, Wei Yudan, Zhang Haiying, Shi Yanfen, Li Yulin, Li Ronggui, Arsenic trioxide induces apoptosis of p53 null osteosarcoma MG63 cells through the inhibition of catalase, 10.1007/s12032-011-9848-5
  34. Coe Emma, Schimmer Aaron D., Catalase activity and arsenic sensitivity in acute leukemia, 10.1080/10428190802353617
  35. Song Li-Li, Tu Yao-Yao, Xia Li, Wang Wei-Wei, Wei Wei, Ma Chun-Min, Wen Dong-Hua, Lei Hu, Xu Han-Zhang, Wu Ying-Li, Targeting Catalase but Not Peroxiredoxins Enhances Arsenic Trioxide-Induced Apoptosis in K562 Cells, 10.1371/journal.pone.0104985
  36. Subbarayan Pochi R., Ardalan Bach, In the War Against Solid Tumors Arsenic Trioxide Need Partners, 10.1007/s12029-014-9617-8
  37. Fiskus Warren, Coothankandaswamy Veena, Chen Jianguang, Ma Hongwei, Ha Kyungsoo, Saenz Dyana T., Krieger Stephanie S., Mill Christopher P., Sun Baohua, Huang Peng, Mumm Jeffrey S., Melnick Ari M., Bhalla Kapil N., SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents, 10.1158/0008-5472.can-16-0126
  38. Yun Sun-Mi, Woo Sang Hyeok, Oh Sang Taek, Hong Sung-Eun, Choe Tae-Boo, Ye Sang-Kyu, Kim Eun-Kyu, Seong Min Ki, Kim Hyun-A, Noh Woo Chul, Lee Jin Kyung, Jin Hyeon-Ok, Lee Yun-Han, Park In-Chul, Melatonin enhances arsenic trioxide-induced cell death via sustained upregulation of Redd1 expression in breast cancer cells, 10.1016/j.mce.2015.11.016
  39. Glorieux Christophe, Calderon Pedro Buc, Catalase, a remarkable enzyme: targeting the oldest antioxidant enzyme to find a new cancer treatment approach, 10.1515/hsz-2017-0131